Author

Kelvin C. Mo

Observed names: Kelvin C. Mo, Kelvin Mo, Mo, Kelvin C.

Institutions: Harvard University, Parker Institute for Cancer Immunotherapy, Stanford Medicine, Stanford Cancer Institute, Stanford University

Observed institutions: Harvard University, Parker Institute for Cancer Immunotherapy, Stanford Medicine, Stanford Cancer Institute, Stanford University

ORCID: 0009-0002-5494-6128

Observed ORCID: 0009-0002-5494-6128

OpenAlex ID: A5120419430

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

2026 · Xiaojing Chen, Zhiyuan Mao, et al. · Science · 17

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

2026 · Gregory M. Chen, Ankita Jain, et al. · Nature Biomedical Engineering · 15

Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma

2026 · Yiyun Chen, Kevin Reynolds, et al. · medRxiv · 1

Abstract 6463: Longitudinal single-cell atlas of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma identifies humoral and cellular anti-CAR immunity

2026 · Yiyun Chen, Kun-Wei Song, et al. · Cancer Research · 1

PersonaScienceBench: Evaluating Scientific Agents with Diverse Simulated Researchers

2026 · Wu, Siyang, Zhang, Weizhi, et al. · arXiv (Cornell University)

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

2026 · Matthew Frank, Anne Marijn Kramer, et al. · Research Square

CCL8+CCL13+ tumor-associated macrophages mark early resistance to CAR T cell therapy in large B cell lymphoma

2025 · Kelvin C. Mo, Anne Marijn Kramer, et al. · SSRN Electronic Journal

514 Biomechanical Analysis of Swallow Induced Primary Peristalsis in Patients With Egjoo

2021 · Melissa M. Ledgerwood-Lee, Kelvin C. Mo, et al. · Gastroenterology

Works count: 8

Citation count: 34

H-index: 2

I10-index: 2